ValuentumAd

Official PayPal Seal

Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jun 14, 2017
Bristol-Myers Squibb Disappoints
Shares of Bristol-Myers Squibb have come under intense selling pressure off the heels of disappointing performance at ASCO. Let’s examine the situation.
May 26, 2017
Alexion’s Executive Departures and an Update from Regeneron Pharma
Image shown above: Performance of Regeneron since the summer of 2013.An executive scandal continues to mar the performance of Alexion Pharmaceuticals. The CFO has resigned his position effective the end of August, but there is more to this story. Let’s also talk Regeneron.
May 17, 2017
Coherus Biosciences Begins the Process of Bringing a Humira Biosimilar to Market
Image Source: Drugs.com. The duration and validity of patents that back the intellectual property of drugs in the pharma/biotech industry underpin the group’s revenue stream. Once patent protection is lost, however, revenue from products typically nosedives as multi-source products come to market, undercutting their original price. The patent estate, in essence, bestows monopoly-like pricing power to Big Pharma. Once lost though, it becomes tough to replace. Let’s provide a quick update on the breaking Coherus Biosciences patent win.
Apr 17, 2017
Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players.
Mar 11, 2017
Celgene: A Hemeoncology Powerhouse
Let’s walk through the investment merits of one of the market darlings in biotech.
Feb 23, 2017
3 Critical Drug Approvals For Your Radar
Image Source: Neurocrine Biosciences.  What can investors expect when it comes to imminent drug approvals? Let’s cover three important ones.
Feb 14, 2017
Is AbbVie a Value Trap?
Image Source: Express Scripts. With uncertainty surrounding the patent of blockbuster drug Humira, AbbVie is looking to deliver another success story from its pipeline. Is it headed for a patent cliff? Let’s take a look.
Jan 19, 2017
The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.
Dec 10, 2016
Image: Returns Following the Trump Victory
The stock market is at all-time highs…again. Optimism about what the Trump administration might bring is the main driver, and many are pointing to reduced corporate taxes, translating to higher dividend payments, as reasons to be even more optimistic.
Nov 16, 2016
Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.


Latest News and Media

The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.